SOURCES SOUGHT
Q -- Testing associations between whole blood hydroxychloroquine (HCQ) levels and blood biomarkers of neurodegeneration
- Notice Date
- 6/20/2024 5:25:41 PM
- Notice Type
- Sources Sought
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95024Q00371
- Response Due
- 7/5/2024 7:00:00 AM
- Archive Date
- 07/20/2024
- Point of Contact
- Fred Ettehadieh
- E-Mail Address
-
Fred.Ettehadieh@nih.gov
(Fred.Ettehadieh@nih.gov)
- Description
- This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Background and Objectives: �Research in the National Institute on Aging has identified several FDA approved drugs through the DREAM study that may target metabolic abnormalities associated with AD and be of utility as effective disease-modifying AD treatments. Repurposing of approved drugs is a promising approach that can accelerate the development of novel AD treatments. Through the Drug Repurposing for Effective Alzheimer�s Medicines (DREAM) study, the NIA IRP identified that the HCQ administered to patients with rheumatoid arthritis (RA) lowers the risk of incident AD. Further experimental validation of these findings has been completed in cell culture-based phenotypic assays as well as in studies of long-term potentiation (LTP) in the APP/PS1 transgenic mouse model. In results from the Experimental Validation of candidate Alzheimer�s disease treatments identified by multi-omics analyses (PREVENT-AD) study, we have shown that HCQ may reduce levels of plasma neurofilament-light (NfL), a peripheral biomarker of neurodegeneration. In patients administered HCQ, whole blood levels of the drug vary widely and it is unclear whether alterations in blood HCQ concentrations are associated with blood biomarkers of neurodegeneration in humans. This acquisition has the following objective: 1) To test whether changes in whole blood levels of hydroxychloroquine (HCQ) are associated with alterations in plasma concentrations of blood biomarkers of neurodegeneration in a well-characterized cohort of patients with systemic lupus erythematosus SLE. Project requirements: �Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed.� The objectives of the requirements are:� Testing associations between whole blood hydroxychloroquine (HCQ) levels and blood biomarkers of neurodegeneration Perform assays on plasma samples provided by the NIA IRP using the NULISASeq CNS disease panel to measure 120 biomarkers related to neurodegeneration. 150 microliters each of banked plasma will be provided from 163 unique lupus patients from the Johns Hopkins Lupus cohort (PI; Dr. Michelle Petri). A total of 460 plasma samples will be provided. Anticipated period of performance: September 30, 2024 � September 29, 2025. Capability statement /information sought: Small business concerns that believe they possess the capabilities to provide the required services should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately.� Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Small businesses must also provide their Company Name, Unique Entity ID (UEI) from SAM.gov, Physical Address, and Point of Contact Information. Interested small businesses are required to identify their type of business, applicable North American Industry Classification System Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirements and in the capability statement/information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages.� The 10-page limit does not include the cover page, executive summary, or references, if requested. All capability statements sent in response to this Small Business Sources Sought Notice must be submitted to Fred Ettehadieh, Contracting Officer, by email at fred.ettehadieh@nih.gov before the closing date and time of this announcement. All responses must be received by the specified due date and time in order to be considered. Facsimile responses are not acceptable. �Disclaimer and Important Notes:� This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).�
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/c8f6a35051d5465b84e747eab175ea21/view)
- Place of Performance
- Address: MD, USA
- Country: USA
- Country: USA
- Record
- SN07103470-F 20240622/240620230115 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |